Drug-eluting stents reduce the occurrence of in-stent restenosis and the need for subsequent target vessel revascularization when compared with bare-metal stents. However, drug-eluting stents may ...

Purpose: The mechanism of action and pharmacokinetics of sirolimus when used as part of a drug-eluting stent (DES) and the efficacy and cost of using DESs versus bare-metal stents are discussed.

I’ve heard mixed opinions about stents for treating coronary artery disease. Are they really beneficial, especially for ...

Expanded stent physically opens a blocked blood vessel, but interactions between the metal surface and vascular cells can either promote healing or lead to adverse effects. The research team led ...

The knowns and unknowns about venous thrombus biology as it relates to in-stent restenosis and how these results drive ...

The $90m will be used to launch the second of two pivotal trials examining the company’s therapy for patients living with ...

The VIVA Foundation, in collaboration with representatives from the American Venous Forum (AVF) and American Vein and ...

This surge is primarily driven by the growing demand for minimally invasive procedures to treat cardiovascular diseases, which are on ...

Expanded stent physically opens a blocked blood vessel, but interactions between the metal surface and vascular cells can either promote healing or lead to adverse effects. Credit: Korea Institute ...

Medtronic (NYSE: MDT) announced today that it entered into an exclusive U.S. distribution agreement with Contego Medical.